Current trends in management of hepatitis B virus reactivation in the biologic therapy era

Hepatitis B virus (HBV) reactivation represents an emerging cause of liver disease in patients undergoing treatment with biologic agents. In particular, the risk of HBV reactivation is heightened by the use monoclonal antibodies, such as rituximab (anti-CD20) and alemtuzumab (anti-CD52) that cause p...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Mastroianni, Claudio M, Lichtner, Miriam, Citton, Rita, Borgo, Cosmo Del, Rago, Angela, Martini, Helene, Cimino, Giuseppe, Vullo, Vincenzo
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Baishideng Publishing Group Co., Limited 2011
Pynciau:
Review
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3198017/
https://ncbi.nlm.nih.gov/pubmed/22025876
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v17.i34.3881
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg